CoChat
Sign Up
Cited by 13

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin

Lopes, Rui, Shi, Kevin, Fonseca, Nuno A., Gama, Adelina, Ramalho, José S., Almeida, Luís, Moura, Vera, Simões, Sérgio, Tidor, Bruce, Moreira, João N.·2022·Drug Delivery and Translational Research
DOI 10.1007/s13346-021-00972-z
Open this paper in CoChat — free account

Abstract

Strategies targeting nucleolin have enabled a significant improvement in intracellular bioavailability of their encapsulated payloads. In this respect, assessment of the impact of target cell heterogeneity and nucleolin homology across species (structurally and functionally) is of major importance. This work also aimed at mathematically modelling the nucleolin expression levels at the cell membrane, binding and internalization of pH-sensitive pegylated liposomes encapsulating doxorubicin and functionalized with the nucleolin-binding F3 peptide (PEGASEMP), and resulting cytotoxicity against cancer cells from mouse, rat, canine, and human origin. Herein, it was shown that nucleolin expression levels were not a limitation on the continuous internalization of F3 peptide-targeted liposomes, despite the saturable nature of the binding mechanism. Modeling enabled the prediction of nucleolin-mediated total doxorubicin exposure provided by the experimental settings of the assessment of PEGASEMP's impact on cell death. The former increased proportionally with nucleolin-binding sites, a measure relevant for patient stratification. This pattern of variation was observed for the resulting cell death in nonsaturating conditions, depending on the cancer cell sensitivity to doxorubicin. This approach differs from standard determination of cytotoxic concentrations, which normally report values of incubation doses rather than the actual intracellular bioactive drug exposure. Importantly, in th…

Overview

Integrity signals

Registry

Crossref · 10.1007/s13346-021-00972-z

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 77

  1. Fonseca NA, Moura V, Colelli F, Pesce D, Cardile F, Pisano C, et al. Targeting nucleolin with doxorubicin-containing nanoparticle induces a significant tumor growth inhibition in an orthotopic animal model of standard of care-resistant mesothelioma. Cancer Res. 2017;77:5155. · DOI
  2. Fonseca NA, Gregorio AC, Valerio-Fernandes A, Simoes S, Moreira JN. Bridging cancer biology and the patients’ needs with nanotechnology-based approaches. Cancer Treat Rev. 2014;40:626–35. · DOI
  3. Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev. 2017;117:12133–64. · DOI
  4. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther. 2013;12:1816–28. · DOI
  5. Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer. 2018;119:1086–93. · DOI
  6. Gregorio AC, Lacerda M, Figueiredo P, Simoes S, Dias S, Moreira JN. Meeting the needs of breast cancer: a nucleolin’s perspective. Crit Rev Oncol Hematol. 2018;125:89–101. · DOI
  7. Fonseca NA, Gregório AC, Mendes VM, Lopes R, Abreu T, Gonçalves N, et al. GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure. Nano Today. 2021;37. · DOI
  8. Srivastava M, Pollard HB. Molecular dissection of nucleolin’s role in growth and cell proliferation: new insights. FASEB J. 1999;13:1911–22. · DOI
  9. Gaume X, Tassin AM, Ugrinova I, Mongelard F, Monier K, Bouvet P. Centrosomal nucleolin is required for microtubule network organization. Cell Cycle. 2015;14:902–19. · DOI
  10. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8:66. · DOI
  11. Xu JY, Lu S, Xu XY, Hu SL, Li B, Li WX, et al. Prognostic significance of nuclear or cytoplasmic nucleolin expression in human non-small cell lung cancer and its relationship with DNA-PKcs. Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:10349–56. · DOI
  12. Jain N, Zhu H, Khashab T, Ye Q, George B, Mathur R, et al. Targeting nucleolin for better survival in diffuse large B-cell lymphoma. Leukemia. 2018;32:663–74. · DOI
  13. Qiu W, Zhou F, Zhang Q, Sun X, Shi X, Liang Y, et al. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer. APMIS. 2013;121:919–25. · DOI
  14. Chen C, Chen L, Yao Y, Qin Z, Chen H. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients. J Neurooncol. 2016;127:43–52. · DOI
  15. Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, et al. Expression profiling of ribosome biogenesis factors reveals nucleolin as a novel potential marker to predict outcome in AML patients. PLoS ONE. 2017;12:e0170160. · DOI
  16. Berger CM, Gaume X, Bouvet P. The roles of nucleolin subcellular localization in cancer. Biochimie. 2015;113:78–85. · DOI
  17. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003;163:871–8. · DOI
  18. Fonseca NA, Cruz AF, Moura V, Simoes S, Moreira JN. The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors. Crit Rev Oncol Hematol. 2017;113:111–21. · DOI
  19. Hovanessian AG, Soundaramourty C, Khoury DE, Nondier I, Svab J, Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS ONE. 2010;5:e15787. · DOI
  20. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A. 2002;99:7444–9. · DOI
  21. Lauffenburger DA, Linderman J, Berkowitz L. Analysis of mammalian cell growth factor receptor dynamics. Ann N Y Acad Sci. 1987;506:147–62. · DOI
  22. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 2004;64:3479–85. · DOI · Paper page
  23. Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregorio AC, Valerio-Fernandes A, et al. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Biomaterials. 2015;69:76–88. · DOI
  24. Xiong Q, Wilson WK, Pang J. The Liebermann-Burchard reaction: sulfonation, desaturation, and rearrangment of cholesterol in acid. Lipids. 2007;42:87–96. · DOI
  25. Moura V, Lacerda M, Figueiredo P, Corvo ML, Cruz ME, Soares R, et al. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer. Breast Cancer Res Treat. 2012;133:61–73. · DOI
  26. Fonseca NA, Gomes-da-Silva LC, Moura V, Simoes S, Moreira JN. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. J Control Release. 2014;196:122–31. · DOI
  27. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7:539. · DOI
  28. Said EA, Courty J, Svab J, Delbe J, Krust B, Hovanessian AG. Pleiotrophin inhibits HIV infection by binding the cell surface-expressed nucleolin. FEBS J. 2005;272:4646–59. · DOI
  29. Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG. The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor. J Biol Chem. 2002;277:37492–502. · DOI
  30. Nisole S, Krust B, Hovanessian AG. Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res. 2002;276:155–73. · DOI
  31. Cherry RJ, Smith PR, Morrison IEG, Fernandez N. Mobility of cell surface receptors: a re-evaluation. FEBS Lett. 1998;430:88–91. · DOI
  32. Lauffenburger DA, Linderman JJ. Receptors. Models for binding, trafficking, and signalling. The International Journal of Biochemistry & Cell Biology. 1996;28. · DOI
  33. Thoumine O, Saint-Michel E, Dequidt C, Falk J, Rudge R, Galli T, et al. Weak effect of membrane diffusion on the rate of receptor accumulation at adhesive contacts. Biophys J. 2005;89:L40–2. · DOI
  34. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol. 2012;1:147–68. · DOI
  35. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017;9. · DOI
  36. Perelson AS. Receptor clustering on a cell surface. III. theory of receptor cross-linking by multivalent ligands: description by ligand states. Mathematical Biosciences. 1981;53:1–39. · DOI
  37. Nir S, Peled R, Lee K-D. Analysis of particle uptake by cells: Binding to several receptors, equilibration time, endocytosis. Colloids Surf, A. 1994;89:45–57. · DOI
  38. Xu H, Shaw DE. A simple model of multivalent adhesion and its application to influenza infection. Biophys J. 2016;110:218–33. · DOI
  39. Straubinger RM, Hong K, Friend DS, Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. Cell. 1983;32:1069–79. · DOI
  40. Daleke DL, Hong K, Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1990;1024:352–66. · DOI
  41. Düzgüneş N, Nir S. Mechanisms and kinetics of liposome–cell interactions. Adv Drug Deliver Rev. 1999;40:3–18. · DOI
  42. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007;59:748–58. · DOI
  43. Zhu J, Miao Q, Tang J, Wang X, Dong D, Liu T, et al. Nucleolin mediates the internalization of rabbit hemorrhagic disease virus through clathrin-dependent endocytosis. PLoS Pathog. 2018;14:e1007383. · DOI
  44. Birtwistle MR, Kholodenko BN. Endocytosis and signalling: a meeting with mathematics. Mol Oncol. 2009;3:308–20. · DOI
  45. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440–6. · DOI
  46. Šimůnek T, Štěrba M, Popelová O, Adamcová M, Hrdina R, Geršl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154–71. · DOI
  47. Brown MS, Anderson RGW, Goldstein JL. Recycling receptors: The round-trip itinerary of migrant membrane proteins. Cell. 1983;32:663–7. · DOI · Paper page
  48. Moehren G, Markevich N, Demin O, Kiyatkin A, Goryanin I, Hoek JB, et al. Temperature dependence of the epidermal growth factor receptor signaling network can be accounted for by a kinetic model. Biochemistry. 2002;41:306–20. · DOI
  49. Tomoda H, Kishimoto Y, Lee YC. Temperature effect on endocytosis and exocytosis by rabbit alveolar macrophages. J Biol Chem. 1989;264:15445–50. · DOI
  50. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008;22:633–48. · DOI · Paper page
  51. Eliaz RE, Nir S, Marty C, Szoka FC Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004;64:711–8. · DOI
  52. Waters CM, Oberg KC, Carpenter G, Overholser KA. Rate constants for binding, dissociation, and internalization of EGF: effect of receptor occupancy and ligand concentration. Biochemistry. 1990;29:3563–9. · DOI
  53. Bourbon H-M, Lapeyre B, Amalric F. Structure of the mouse nucleolin gene. J Mol Biol. 1988;200:627–38. · DOI
  54. Bourbon H-M, Amalric F. Nucleolin gene organization in rodents: highly conserved sequenced within three of the 13 introns. Gene. 1990;88:187–96. · DOI
  55. Srivastava M, Fleming PJ, Pollard HB, Burns AL. Cloning and sequencing of the human nucleolin cDNA. FEBS Lett. 1989;250:99–105. · DOI
  56. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 2005;438:803–19. · DOI · Paper page
  57. Serin G, Joseph G, Faucher C, Ghisolfi L, Bouche G, Amalric F, et al. Localization of nucleolin binding sites on human and mouse pre-ribosomal RNA. Biochimie. 1996;78:530–8. · DOI
  58. González-Camacho F, Medina FJ. Nucleolins from different model organisms have conserved sequences reflecting the conservation of key cellular functions through evolution. J Appl Biomed. 2004;2:151–61. · DOI
  59. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci. 1999;112(Pt 6):761–72. · DOI
  60. Mongelard F, Bouvet P. Nucleolin: a multiFACeTed protein. Trends Cell Biol. 2007;17:80–6. · DOI
  61. Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: the most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol. 2011;4:267–75. · DOI
  62. Epstein H, Afergan E, Moise T, Richter Y, Rudich Y, Golomb G. Number-concentration of nanoparticles in liposomal and polymeric multiparticulate preparations: empirical and calculation methods. Biomaterials. 2006;27:651–9. · DOI
  63. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol. 1997;15:1906–15. · DOI
  64. Pinto AC, Moreira JN, Simoes S. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol. 2009;64:445–54. · DOI
  65. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–60. · DOI · Paper page
  66. Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, et al. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun. 2018;9:5137. · DOI
  67. Leahy DJ. Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. Adv Protein Chem. 2004;68:1–27. · DOI
  68. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15:5268–82. · DOI
  69. Chen X, Kube DM, Cooper MJ, Davis PB. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther. 2008;16:333–42. · DOI
  70. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. · DOI · Paper page
  71. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, et al. Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018;12:1838–55. · DOI
  72. Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–78. · DOI · Paper page
  73. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. · DOI · Paper page
  74. Gedye CA, Hussain A, Paterson J, Smrke A, Saini H, Sirskyj D, et al. Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity. PLoS ONE. 2014;9:e105602. · DOI
  75. Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O'Toole MG, Trent JO. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Biochimica et Biophysica Acta (BBA) - General Subjects. 2017;1861:1414–28. · DOI
  76. Hu Q, Gu G, Liu Z, Jiang M, Kang T, Miao D, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials. 2013;34:1135–45. · DOI
  77. Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010;70:8674–83. · DOI

Cited by

Sorted by citations

Metadata

Authors
Lopes, R., Shi, K., Fonseca, N. A., Gama, A., Ramalho, J. S., Almeida, L., Moura, V., Simões, S., Tidor, B., & Moreira, J. N.
Venue
Drug Delivery and Translational Research
Publisher
Springer Science and Business Media LLC
Published
2021-04-15
Volume
12
Issue
3
Pages
629-646
ISSN
  • 2190-393X
  • 2190-3948
DOI
10.1007/s13346-021-00972-z
Cited by
13
References
1
Language
en
Licence
Funders
  • QREN/FEDER (23240)
  • ERDF-Centro (CENTRO-01-0247-FEDER-017646 (ODD4PEGASEMP))
  • Fundação para a Ciência e a Tecnologia (POCI-01-0145-FEDER-016390 (CancelStem), Euronanomed (FCT reference ENMed/0005/2015), CENTRO-01-0145-FEDER-000012-HealthyAging2020, CIBB (FCT reference UIDB/04539/2020))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review